Intuitive announced FDA clearance for the da Vinci SP system to perform inguinal hernia, cholecystectomy, and appendectomy procedures.
Quiver AI Summary
Intuitive, a leader in minimally invasive care and robotic-assisted surgery, has received FDA clearance for its da Vinci Single Port (SP) surgical system, allowing it to be used in inguinal hernia repair, cholecystectomy, and appendectomy procedures. This expands the system's capabilities beyond its existing clearances in various surgical fields. The da Vinci SP is designed for advanced surgical techniques through a single port, offering improved precision and visualization for surgeons. Intuitive continues to innovate, aiming to enhance patient care by facilitating less invasive procedures that reduce recovery times and costs. The effectiveness and safety of the da Vinci SP system are supported by extensive research, and it is also approved for use in several countries including Europe, Japan, and Korea.
Potential Positives
- The FDA clearance for the da Vinci Single Port (SP) surgical system significantly expands its capabilities, allowing for use in inguinal hernia repair, cholecystectomy, and appendectomy procedures.
- This expansion enhances the da Vinci SP system's market competitiveness and offers surgeons advanced capabilities for performing minimally invasive surgeries.
- The positive support from over 500 peer-reviewed publications reinforces the safety and efficacy of the da Vinci SP system, boosting credibility among medical professionals.
- The company’s commitment to innovation and evolving the da Vinci platform aligns with ongoing trends in healthcare toward less invasive surgical options, which may lead to better patient outcomes and increased market demand.
Potential Negatives
- The press release does not provide specific details on how the newly cleared procedures will impact market share or competition, leaving uncertainty about the potential financial benefits of the clearance.
- There is no mention of how this new clearance addresses any existing concerns or criticisms related to the da Vinci SP system, which may leave stakeholders questioning product safety and efficacy.
- The press release lacks quantitative data or specific market projections associated with the clearance, which may diminish investor confidence in the anticipated growth from this development.
FAQ
What new procedures are approved for the da Vinci SP system?
The FDA has cleared the da Vinci SP system for inguinal hernia repair, cholecystectomy, and appendectomy procedures.
How does the da Vinci SP system enhance surgical precision?
The system allows surgeons to control up to three multi-jointed instruments and a 3DHD endoscope through a single incision.
What are the benefits of using the da Vinci SP for surgeries?
The da Vinci SP supports less invasive approaches, reduces recovery time, and can lower overall costs of care.
Is the da Vinci SP system approved outside the US?
Yes, the da Vinci SP system is also approved for use in Europe, Japan, and Korea for multiple procedures.
What is Intuitive's vision for the future of patient care?
Intuitive envisions a future of care that is less invasive, focusing on early disease identification and quick treatment.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ISRG Insider Trading Activity
$ISRG insiders have traded $ISRG stock on the open market 29 times in the past 6 months. Of those trades, 0 have been purchases and 29 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by insiders over the last 6 months:
- GARY S GUTHART (Executive Chair of the Board o) has made 0 purchases and 8 sales selling 94,459 shares for an estimated $49,513,559.
- DAVID J. ROSA (Chief Executive Officer (CEO)) sold 24,500 shares for an estimated $13,414,979
- HENRY L CHARLTON (EVP & Chief Commercial and Mkt) has made 0 purchases and 5 sales selling 13,731 shares for an estimated $7,963,980.
- MYRIAM CURET (EVP & Chief Medical Officer) has made 0 purchases and 7 sales selling 12,417 shares for an estimated $6,561,151.
- BRIAN EDWARD MILLER (EVP & Chief Digital Officer) has made 0 purchases and 2 sales selling 3,500 shares for an estimated $2,012,500.
- CRAIG H BARRATT has made 0 purchases and 2 sales selling 2,943 shares for an estimated $1,636,785.
- FREDRIK WIDMAN (VP Corporate Controller) has made 0 purchases and 2 sales selling 2,067 shares for an estimated $1,136,850.
- AMY L LADD has made 0 purchases and 2 sales selling 671 shares for an estimated $305,588.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$ISRG Revenue
$ISRG had revenues of $2.5B in Q3 2025. This is an increase of 22.91% from the same period in the prior year.
You can track ISRG financials on Quiver Quantitative's ISRG stock page.
$ISRG Congressional Stock Trading
Members of Congress have traded $ISRG stock 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ISRG stock by members of Congress over the last 6 months:
- SENATOR MARKWAYNE MULLIN purchased up to $100,000 on 09/24.
- REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 09/03.
- REPRESENTATIVE LISA C. MCCLAIN has traded it 2 times. They made 1 purchase worth up to $15,000 on 07/10 and 1 sale worth up to $15,000 on 07/16.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$ISRG Hedge Fund Activity
We have seen 1,005 institutional investors add shares of $ISRG stock to their portfolio, and 1,139 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 4,175,405 shares (-54.4%) from their portfolio in Q3 2025, for an estimated $1,867,366,378
- FMR LLC removed 3,659,932 shares (-42.3%) from their portfolio in Q3 2025, for an estimated $1,636,831,388
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 2,899,223 shares (+84.4%) to their portfolio in Q3 2025, for an estimated $1,296,619,502
- D. E. SHAW & CO., INC. added 1,388,122 shares (+220.1%) to their portfolio in Q3 2025, for an estimated $620,809,802
- CAPITAL RESEARCH GLOBAL INVESTORS removed 1,302,661 shares (-45.6%) from their portfolio in Q3 2025, for an estimated $582,589,079
- WCM INVESTMENT MANAGEMENT, LLC removed 1,189,761 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $646,528,025
- MASSACHUSETTS FINANCIAL SERVICES CO /MA/ removed 1,146,204 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $512,616,814
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ISRG Analyst Ratings
Wall Street analysts have issued reports on $ISRG in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wells Fargo issued a "Overweight" rating on 10/22/2025
- Raymond James issued a "Outperform" rating on 10/22/2025
- Piper Sandler issued a "Overweight" rating on 10/22/2025
- BTIG issued a "Buy" rating on 10/22/2025
- Truist Securities issued a "Buy" rating on 10/22/2025
- RBC Capital issued a "Outperform" rating on 10/22/2025
To track analyst ratings and price targets for $ISRG, check out Quiver Quantitative's $ISRG forecast page.
$ISRG Price Targets
Multiple analysts have issued price targets for $ISRG recently. We have seen 8 analysts offer price targets for $ISRG in the last 6 months, with a median target of $601.5.
Here are some recent targets:
- Danielle Antalffy from UBS set a target price of $600.0 on 10/23/2025
- Shagun Singh from RBC Capital set a target price of $625.0 on 10/22/2025
- Jayson Bedford from Raymond James set a target price of $603.0 on 10/22/2025
- Larry Biegelsen from Wells Fargo set a target price of $600.0 on 10/22/2025
- Adam Maeder from Piper Sandler set a target price of $610.0 on 10/22/2025
- Richard Newitter from Truist Securities set a target price of $620.0 on 10/22/2025
- Ryan Zimmerman from BTIG set a target price of $589.0 on 10/22/2025
Full Release
SUNNYVALE, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the da Vinci Single Port (SP) surgical system for use in inguinal hernia repair, cholecystectomy, and appendectomy procedures.
These clearances expand da Vinci SP’s capabilities and build on its existing U.S. clearances in urology, colorectal, thoracic and transoral procedures.
“Da Vinci SP was designed to give surgeons advanced capability through a single port, offering the precision and control needed in narrow or deep anatomical spaces,” said Iman Jeddi, PhD, Senior Vice President and General Manager, da Vinci Platforms and Product Operations at Intuitive. “This clearance is one part of our innovation pathway for SP. We continue to evolve the platform with new tools and capabilities that help teams pursue less invasive approaches and expand what’s possible with da Vinci SP.”
The da Vinci SP system enables surgeons to perform procedures through a single incision or natural orifice, offering enhanced visualization and precision. Its design supports access to anatomy by allowing surgeons to control up to three multi-jointed instruments and an articulating 3DHD endoscope through one entry point.
“Advancing da Vinci SP is part of our long-term commitment to helping improve the future of patient care — supporting approaches that are less invasive, reduce recovery time, lower the total cost of care, and create a better experience for patients as they return to their lives,” said Myriam Curet, MD, Executive Vice President and Chief Medical Officer at Intuitive. “As we continue to innovate across our platforms, we remain focused on helping more patients access the benefits of minimally invasive care.”
A growing body of evidence, including more than 500 peer-reviewed publications, supports the safety, efficacy, and outcomes associated with the da Vinci SP system. SP is also approved for use in Europe, Japan, and Korea for a range of procedures spanning multiple surgical disciplines.
About Intuitive
Intuitive (NASDAQ: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.
About da Vinci Surgical Systems
There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.
For more information, please visit the company’s website at
www.intuitive.com
.
Important Safety Information
For product intended use and/or indications for use, risks, cautions, and warnings and full prescribing information, visit https://manuals.intuitivesurgical.com/market . For summary of the risks associated with surgery refer to www.intuitive.com/safety .